Page 2
Depletion of regulatory T cells enhancing the anti-tumor effect of in situ vaccination in solid tumors.
Xie YJ, Tian S, Huang M, Lu LL, Liu ZQ, Chen JH, Fan XX. Xie YJ, et al. Pharmacol Res. 2024 May;203:107174. doi: 10.1016/j.phrs.2024.107174. Epub 2024 Apr 3. Pharmacol Res. 2024. PMID: 38580185 Free article.
The emergence of immune checkpoint inhibitors (ICIs) has revolutionized the clinical treatment for tumor. However, the low response rate of ICIs remains the major obstacle for curing patients and effective approaches for patients with primary or secondary resistance to ICI …
The emergence of immune checkpoint inhibitors (ICIs) has revolutionized the clinical treatment for tumor. However, the low response r …
Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma.
Rozera C, Cappellini GA, D'Agostino G, Santodonato L, Castiello L, Urbani F, Macchia I, Aricò E, Casorelli I, Sestili P, Montefiore E, Monque D, Carlei D, Napolitano M, Rizza P, Moschella F, Buccione C, Belli R, Proietti E, Pavan A, Marchetti P, Belardelli F, Capone I. Rozera C, et al. J Transl Med. 2015 May 2;13:139. doi: 10.1186/s12967-015-0473-5. J Transl Med. 2015. PMID: 25933939 Free PMC article. Clinical Trial.
DCs generated in presence of interferon-alpha (IFN-DCs), due to their features of partially mature DCs, capable of efficiently up-taking, processing and cross-presenting antigens to T cells, could successfully carry out this task. Combining intratumoral immunization with t …
DCs generated in presence of interferon-alpha (IFN-DCs), due to their features of partially mature DCs, capable of efficiently up-taking, pr …
Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity.
Schettini J, Kidiyoor A, Besmer DM, Tinder TL, Roy LD, Lustgarten J, Gendler SJ, Mukherjee P. Schettini J, et al. Cancer Immunol Immunother. 2012 Nov;61(11):2055-65. doi: 10.1007/s00262-012-1264-y. Epub 2012 Apr 28. Cancer Immunol Immunother. 2012. PMID: 22543528 Free PMC article.
Moreover, MyD88-deficient NK cells can perform ADCC in vitro. Furthermore, intratumoral injections of CpG ODN-conjugated HMFG-2 induced a significant reduction in tumor burden in vivo in an established model of pancreatic tumor in nude mice compared to CpG ODN or the HMFG- …
Moreover, MyD88-deficient NK cells can perform ADCC in vitro. Furthermore, intratumoral injections of CpG ODN-conjugated HMFG-2 induc …
The Application of 2d Mxene Nanosheet -Based Thermosensitive Gel Delivery System Loaded with Cisplatin and Imiquimod for Lung Cancer.
Ma Y, Jiang T, Zhang R, Liu F, Song S, Zhang H, Huang J, He Z. Ma Y, et al. Int J Nanomedicine. 2024 May 25;19:4719-4733. doi: 10.2147/IJN.S449541. eCollection 2024. Int J Nanomedicine. 2024. PMID: 38813391 Free PMC article.
To tackle lung cancer effectively, we devised a temperature-sensitive hydrogel-based local injection system with near-infrared triggered drug release. Utilizing 2D MXene nanosheets as carriers loaded with R837 and cisplatin (DDP), encapsulated within a temperature-s …
To tackle lung cancer effectively, we devised a temperature-sensitive hydrogel-based local injection system with near-infrared tri …
Injectable polypeptide-engineered hydrogel depot for amplifying the anti-tumor immune effect induced by chemo-photothermal therapy.
Hou XL, Dai X, Yang J, Zhang B, Zhao DH, Li CQ, Yin ZY, Zhao YD, Liu B. Hou XL, et al. J Mater Chem B. 2020 Sep 30;8(37):8623-8633. doi: 10.1039/d0tb01370f. J Mater Chem B. 2020. PMID: 32821893
The water-soluble drug DOX and Bestatin were integrated into the PC10ARGD hydrogel. The photothermal effect could trigger the sustained release of the DOX, which could be applied to initiate in situ vaccination. Bestatin as an immune-adjuvant drug could ampli …
The water-soluble drug DOX and Bestatin were integrated into the PC10ARGD hydrogel. The photothermal effect could trigger the sustain …
The altering cellular components and function in tumor microenvironment during remissive and relapsed stages of anti-CD19 CAR T-cell treated lymphoma mice.
Zhao K, Ren C, Tang D, Zhao L, Chen X, Wang Y, Xu K. Zhao K, et al. Front Immunol. 2023 Jan 25;14:1101769. doi: 10.3389/fimmu.2023.1101769. eCollection 2023. Front Immunol. 2023. PMID: 36761733 Free PMC article.
Compared to mice without anti-CD19 CAR T administration, intrinsic T cells were triggered to produce more IFN-gamma and TNF-alpha. However, some lymphoma mice relapsed by day 42 after therapy, which coincided with CAR T-cell recession, decreased myeloid cell activation and …
Compared to mice without anti-CD19 CAR T administration, intrinsic T cells were triggered to produce more IFN-gamma and TNF-alpha. Ho …
Tong-Xie-Yao-Fang promotes dendritic cells maturation and retards tumor growth in colorectal cancer mice with chronic restraint stress.
Jiang Y, Hu Y, Yang Y, Yan R, Zheng L, Fu X, Xiao C, You F. Jiang Y, et al. J Ethnopharmacol. 2024 Jan 30;319(Pt 1):117069. doi: 10.1016/j.jep.2023.117069. Epub 2023 Aug 22. J Ethnopharmacol. 2024. PMID: 37619860
The results of flow cytometry showed that TXYF can promote the maturation of DCs phenotype and function, enhance antigen presentation ability, increase the ratio of CD4(+) T cells and CD4(+)/CD8(+) T cells, and shift Th1/Th2 balance towards Th1 cells, thus increasing serum levels …
The results of flow cytometry showed that TXYF can promote the maturation of DCs phenotype and function, enhance antigen presentation abilit …
Whole-Component Antigen Nanovaccines Combined With aTIGIT for Enhanced Innate and Adaptive Anti-tumor Immunity.
Wang W, Wu H, Zhang X, Hong Y, Tao S, Cao X, Wang S, Zha L, Zha Z. Wang W, et al. Small. 2025 Mar;21(12):e2412800. doi: 10.1002/smll.202412800. Epub 2025 Feb 18. Small. 2025. PMID: 39967373
Using entire tumor cells or tissues that display both common and patient-specific antigens can potentially trigger a comprehensive and long-lasting anti-tumor immune response. However, the limited immunogenicity, low uptake efficiency, and susceptibili …
Using entire tumor cells or tissues that display both common and patient-specific antigens can potentially trigger a comprehensive an …
Chemotherapy based on HPMA copolymer conjugates with pH-controlled release of doxorubicin triggers anti-tumor immunity.
Mrkvan T, Sirova M, Etrych T, Chytil P, Strohalm J, Plocova D, Ulbrich K, Rihova B. Mrkvan T, et al. J Control Release. 2005 Dec 10;110(1):119-29. doi: 10.1016/j.jconrel.2005.09.028. Epub 2005 Nov 2. J Control Release. 2005. PMID: 16269198
A novel class of anti-cancer therapeutics - polymeric conjugates of N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers and doxorubicin with pH-controlled release of the drug - is highly efficient in killing tumor cells in vitro and is potent in eradicating growing tumors …
A novel class of anti-cancer therapeutics - polymeric conjugates of N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers and doxorubic …
Perilymphatic injections of cytokines: a new tool in active cancer immunotherapy. Experimental rationale and clinical findings.
Forni G, Giovarelli M, Jemma C, Bosco MC, Caretto P, Modesti A, Santoni A, Forni M, Cortesina G, de Stefani A, et al. Forni G, et al. Ann Ist Super Sanita. 1990;26(3-4):397-409. Ann Ist Super Sanita. 1990. PMID: 2151108 Review.
The local injection of cocktails of molecularly defined lymphokines can also mimic the helper action of lymphocytes and trigger a similarly effective anti-tumor reaction. A set of pilot clinical trials with IL-2 or gamma-IFN injected perilymphat …
The local injection of cocktails of molecularly defined lymphokines can also mimic the helper action of lymphocytes and trigger …